Medicure Finishes at New 7-Year Closing High of $4.44: Double Digits Will Be Here Shortly

Medicure (TSXV: MPH) gained by 0.91% today to a new 7-year closing high of $4.44 per share and will be double digits shortly that is a 100% fact. Either research MPH right now or you will pay a much higher price later:

According to the CBO, out of every 100 drugs that enter Phase 1 trials, only 20 make it to Phase 3 trials and 12 get approved, but 60% of drugs in Phase 3 trials get approved.

Almost all US$30 million market cap biotech companies are in Phase 1 trials with a 12% chance of approval. MPH is in Phase 3 trials with a 60% chance of approval.

If MPH gets approval, they receive an FDA Priority Review Voucher that can be sold, with recent transactions for them all selling for more than US$200 million.

MPH should at least be worth US$120 million right now, if not more.

We think the odds of MPH getting approval for MC-1 are actually more than 90%. MPH’s lead investigator, Dr. Phillip Pearl, is the #1 top guy in the world, Boston Children’s Hospital is the #1 best in the world, and Harvard Medical School is the #1 best in the world. Click here to see him talk about how MPH’s drug works!

Past performance is not indicative of future results. NIA is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. NIA’s President has purchased 87,000 shares of MPH and intends to buy more shares. This communication is for informational and educational purposes only.